CAR-T for Relapsed/Refractory AML: From Discovery to First-in-Human Active Phase 1 Evaluation

Join Dr. Marco Davila to explore a novel anti-CD83 CAR-T design for relapsed/refractory AML that overcomes myelosuppression barriers. Register for the live session. Developing effective Chimeric Antigen Receptor (CAR) T-cell…